4//SEC Filing
Newton Charles W. 4
Accession 0001415889-25-022741
CIK 0001806952other
Filed
Aug 21, 8:00 PM ET
Accepted
Aug 22, 4:03 PM ET
Size
8.1 KB
Accession
0001415889-25-022741
Insider Transaction Report
Form 4
Newton Charles W.
Chief Financial Officer
Transactions
- Award
Common Stock
2025-08-20+8,000→ 16,759 total - Sale
Common Stock
2025-08-21$10.54/sh−1,453$15,320→ 15,306 total
Holdings
- 10,000(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date.
- [F2]Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
- [F3]The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- [F4]Shares held by The Charles & Lisa Newton Living Trust. The Reporting Person is co-trustee and co-grantor of The Charles & Lisa Newton Living Trust.
Documents
Issuer
Lyell Immunopharma, Inc.
CIK 0001806952
Entity typeother
Related Parties
1- filerCIK 0001866219
Filing Metadata
- Form type
- 4
- Filed
- Aug 21, 8:00 PM ET
- Accepted
- Aug 22, 4:03 PM ET
- Size
- 8.1 KB